Small Macrocycles As Highly Active Integrin α2β1 Antagonists
摘要:
Starting from clinical candidates Firategrast, Valategrast, and AJM-300, a series of novel macrocyclic platelet collagen receptor alpha 2 beta 1 antagonists were developed. The amino acid derived low molecular weight 14-18-membered macrocycles turned out to be highly active toward integrin alpha 2 beta 1 with IC(50)s in the low nanomolar range. The conformation of the macrocycles was found to be highly important for the activity, and an X-ray crystal structure was obtained to clarify this. Subsequent docking into the metal-ion-dependent adhesion site (MIDAS) of a beta 1 unit revealed a binding model indicating key binding features. Macrocycle 38 was selected for further in vitro and in vivo profiling.
[EN] PYRIMIDINE AND PYRIDINE DERIVATIVES AS HPK1 MODULATOR AND METHODS USING SAME [FR] DÉRIVÉS DE PYRIMIDINE ET DE PYRIDINE EN TANT QUE MODULATEURS DE HPK1 ET LEURS PROCÉDÉS D'UTILISATION
[EN] PYRIMIDINE AND PYRIDINE DERIVATIVES AS HPK1 MODULATOR AND METHODS USING SAME<br/>[FR] DÉRIVÉS DE PYRIMIDINE ET DE PYRIDINE EN TANT QUE MODULATEURS DE HPK1 ET LEURS PROCÉDÉS D'UTILISATION
申请人:SHENZHEN IONOVA LIFE SCIENCE CO LTD
公开号:WO2022063140A1
公开(公告)日:2022-03-31
Provided are heteroaryl compounds of Formula (I) or a pharmaceutically acceptable salt, ester, or prodrug thereof.
提供的是化合物Formula(I)的杂环芳基化合物或其药用可接受的盐、酯或前药。
Small Macrocycles As Highly Active Integrin α2β1 Antagonists
Starting from clinical candidates Firategrast, Valategrast, and AJM-300, a series of novel macrocyclic platelet collagen receptor alpha 2 beta 1 antagonists were developed. The amino acid derived low molecular weight 14-18-membered macrocycles turned out to be highly active toward integrin alpha 2 beta 1 with IC(50)s in the low nanomolar range. The conformation of the macrocycles was found to be highly important for the activity, and an X-ray crystal structure was obtained to clarify this. Subsequent docking into the metal-ion-dependent adhesion site (MIDAS) of a beta 1 unit revealed a binding model indicating key binding features. Macrocycle 38 was selected for further in vitro and in vivo profiling.